GSK2881078 clinical trials
Also written GSK2881078.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses GSK2881078 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GSK2881078
- 3
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Anabolic Agents source
Studies
Open first, then newest update. How each study uses GSK2881078 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT03359473Written as GSK2881078
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat DosesCompletedPhase 1GlaxoSmithKlineNCT02045940Written as GSK2881078
- Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078CompletedPhase 1GlaxoSmithKlineNCT02567773Written as GSK2881078
Codes
What other systems call GSK2881078 · ClinicalTrials.gg INT000940
- MeSH (NLM) C000627232GSK2881078Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 47M5ZXU844GSK-2881078Confirmed NLM, Wikidata
- Wikidata Q96378990GSK2881078Confirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627232 | GSK2881078 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 47M5ZXU844 | GSK-2881078 | Confirmed NLM, Wikidata |
| Wikidata | Q96378990 | GSK2881078 | Confirmed NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.